Symbols / VNDA Stock $6.39 -0.62% Vanda Pharmaceuticals Inc.

Healthcare • Biotechnology • United States • NGM
VNDA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Mihael H. Polymeropoulos M.D.
Exch · Country NGM · United States
Market Cap 384.27M
Enterprise Value 195.03M
Income -239.55M
Sales 217.78M
FCF (ttm) -83.15M
Book/sh 5.54
Cash/sh 3.36
Employees 533
Insider 10d —
IPO Apr 12, 2006
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 31.95
PEG 2.23
P/S 1.76
P/B 1.15
P/C —
EV/EBITDA -1.28
EV/Sales 0.90
Quick Ratio 1.91
Current Ratio 2.16
Debt/Eq 4.66
LT Debt/Eq —
EPS (ttm) -4.06
EPS next Y 0.20
EPS Growth —
Revenue Growth 3.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-05-06
ROA -18.81%
ROE -60.48%
ROIC —
Gross Margin 94.18%
Oper. Margin -97.11%
Profit Margin -109.99%
Shs Outstand 60.14M
Shs Float 54.20M
Insider Own 6.16%
Instit Own 72.94%
Short Float 10.82%
Short Ratio 5.72
Short Interest 6.20M
52W High 9.94
vs 52W High -35.71%
52W Low 3.89
vs 52W Low 64.27%
Beta 0.65
Impl. Vol. 4.30%
Rel Volume 0.29
Avg Volume 2.52M
Volume 727.18K
Target (mean) $14.90
Tgt Median $17.00
Tgt Low $7.50
Tgt High $21.00
# Analysts 5
Recom Strong_buy
Prev Close $6.43
Price $6.39
Change -0.62%
About

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.90
Mean price target
2. Current target
$6.39
Latest analyst target
3. DCF / Fair value
$-24.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.39
Low
$7.50
High
$21.00
Mean
$14.90

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 main HC Wainwright & Co. Buy → Buy $21
2026-03-05 init Truist Securities — → Buy $18
2026-02-23 main HC Wainwright & Co. Buy → Buy $24
2026-01-05 main HC Wainwright & Co. Buy → Buy $22
2025-12-31 main B. Riley Securities Buy → Buy $14
2025-12-31 main Jefferies Hold → Hold $8
2025-11-19 reit HC Wainwright & Co. Buy → Buy $20
2025-11-05 init B. Riley Securities — → Buy $11
2025-10-30 main Cantor Fitzgerald Overweight → Overweight $11
2025-08-21 reit HC Wainwright & Co. Buy → Buy $20
2025-05-07 reit HC Wainwright & Co. Buy → Buy $20
2025-04-01 reit HC Wainwright & Co. Buy → Buy $20
2025-02-18 main HC Wainwright & Co. Buy → Buy $20
2025-02-04 reit HC Wainwright & Co. Buy → Buy $18
2025-01-28 reit HC Wainwright & Co. Buy → Buy $18
2025-01-21 reit HC Wainwright & Co. Buy → Buy $18
2024-12-23 reit HC Wainwright & Co. Buy → Buy $18
2024-10-31 init HC Wainwright & Co. — → Buy $18
2024-08-01 main Cantor Fitzgerald Overweight → Overweight $13
2024-07-11 init Cantor Fitzgerald — → Overweight $11
News
RSS: Latest VNDA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-22 DUNCAN CHARLES CLIFF Director — 57,101 $0.00 $0
2026-03-02 BIRZNIEKS GUNTHER Officer — 42,431 $8.27 $350,730
2026-03-02 WILLIAMS TIMOTHY IAN General Counsel — 42,434 $8.27 $350,755
2026-03-02 WIJKSTROM JOAKIM PER Officer — 30,800 $8.27 $254,590
2026-03-02 POLYMEROPOULOS MIHAEL HRISTOS Chief Executive Officer — 156,235 $8.17 $1,276,971
2026-03-02 MORAN KEVIN PATRICK Chief Financial Officer — 42,442 $8.27 $350,821
2026-02-23 HONORE TAGE Director — 30,000 $8.03 $240,900
2026-02-18 POLYMEROPOULOS MIHAEL HRISTOS Chief Executive Officer — 525,000 $0.00 $0
2026-02-18 BIRZNIEKS GUNTHER Officer — 125,000 $0.00 $0
2026-02-18 WILLIAMS TIMOTHY IAN General Counsel — 125,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
216.10
+8.72%
198.77
+3.18%
192.64
-24.27%
254.38
Operating Revenue
216.10
+8.72%
198.77
+3.18%
192.64
-24.27%
254.38
Cost Of Revenue
13.04
+15.29%
11.31
-23.53%
14.80
-39.07%
24.28
Reconciled Cost Of Revenue
8.13
-7.44%
8.79
-29.99%
12.55
-45.58%
23.07
Gross Profit
203.06
+8.32%
187.46
+5.41%
177.84
-22.71%
230.10
Operating Expense
354.23
+55.28%
228.12
+18.94%
191.80
-14.29%
223.77
Research And Development
109.27
+46.81%
74.43
-3.11%
76.82
-10.43%
85.77
Selling General And Administration
237.95
+62.52%
146.41
+29.70%
112.88
-17.29%
136.49
Total Expenses
367.27
+53.39%
239.43
+15.90%
206.59
-16.71%
248.05
Operating Income
-151.17
-271.79%
-40.66
-191.43%
-13.95
-320.45%
6.33
Total Operating Income As Reported
-151.17
-271.79%
-40.66
-191.43%
-13.95
-320.45%
6.33
EBITDA
-139.25
-351.22%
-30.86
-220.87%
-9.62
-206.14%
9.06
Normalized EBITDA
-139.25
-351.22%
-30.86
-220.87%
-9.62
-206.14%
9.06
Reconciled Depreciation
11.92
+21.61%
9.80
+126.10%
4.33
+58.58%
2.73
EBIT
-151.17
-271.79%
-40.66
-191.43%
-13.95
-320.45%
6.33
Net Income
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Pretax Income
-138.65
-504.89%
-22.92
-461.59%
6.34
-43.90%
11.30
Other Income Expense
12.52
-29.42%
17.74
-12.58%
20.29
+308.19%
4.97
Other Non Operating Income Expenses
12.52
-29.42%
17.74
-12.58%
20.29
+308.19%
4.97
Tax Provision
81.83
+2134.99%
-4.02
-204.99%
3.83
-23.78%
5.03
Tax Rate For Calcs
0.00
+19.32%
0.00
-16.19%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Net Income From Continuing Operation Net Minority Interest
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Net Income From Continuing And Discontinued Operation
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Net Income Continuous Operations
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Normalized Income
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Net Income Common Stockholders
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Diluted EPS
-3.74
-1033.33%
-0.33
-925.00%
0.04
-63.64%
0.11
Basic EPS
-3.74
-1033.33%
-0.33
-925.00%
0.04
-63.64%
0.11
Basic Average Shares
58.93
+1.34%
58.15
+1.34%
57.38
+1.63%
56.46
Diluted Average Shares
58.93
+1.34%
58.15
+1.03%
57.56
+1.01%
56.98
Diluted NI Availto Com Stockholders
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Amortization
7.01
-3.66%
7.27
+247.99%
2.09
+37.86%
1.52
Amortization Of Intangibles Income Statement
7.01
-3.66%
7.27
+247.99%
2.09
+37.86%
1.52
Depreciation Amortization Depletion Income Statement
7.01
-3.66%
7.27
+247.99%
2.09
+37.86%
1.52
Depreciation And Amortization In Income Statement
7.01
-3.66%
7.27
+247.99%
2.09
+37.86%
1.52
Line Item Trend 2023-12-31
Total Assets
648.44
Current Assets
432.95
Cash Cash Equivalents And Short Term Investments
388.26
Cash And Cash Equivalents
135.82
Other Short Term Investments
252.44
Receivables
34.16
Accounts Receivable
34.16
Inventory
1.36
Work In Process
0.03
Finished Goods
1.33
Prepaid Assets
—
Other Current Assets
9.17
Total Non Current Assets
215.49
Net PPE
9.14
Gross PPE
20.32
Accumulated Depreciation
-11.18
Properties
0.00
Machinery Furniture Equipment
7.78
Other Properties
7.10
Leases
5.44
Goodwill And Other Intangible Assets
121.37
Other Intangible Assets
121.37
Non Current Deferred Assets
75.00
Non Current Deferred Taxes Assets
75.00
Other Non Current Assets
9.98
Total Liabilities Net Minority Interest
103.53
Current Liabilities
87.70
Payables And Accrued Expenses
29.65
Payables
29.65
Accounts Payable
7.14
Other Payable
22.50
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
6.41
Current Debt And Capital Lease Obligation
2.40
Current Capital Lease Obligation
2.40
Total Non Current Liabilities Net Minority Interest
15.83
Long Term Debt And Capital Lease Obligation
7.01
Long Term Capital Lease Obligation
7.01
Other Non Current Liabilities
8.83
Stockholders Equity
544.91
Common Stock Equity
544.91
Capital Stock
0.06
Common Stock
0.06
Preferred Stock
0.00
Share Issued
57.53
Ordinary Shares Number
57.53
Treasury Shares Number
0.00
Additional Paid In Capital
700.27
Retained Earnings
-155.39
Gains Losses Not Affecting Retained Earnings
-0.03
Other Equity Adjustments
-0.03
Total Equity Gross Minority Interest
544.91
Total Capitalization
544.91
Working Capital
345.25
Invested Capital
544.91
Total Debt
9.40
Capital Lease Obligations
9.40
Net Tangible Assets
423.54
Tangible Book Value
423.54
Current Provisions
49.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-109.44
-594.56%
-15.76
-223.09%
12.80
-59.98%
31.98
Cash Flow From Continuing Operating Activities
-109.44
-594.56%
-15.76
-223.09%
12.80
-59.98%
31.98
Net Income From Continuing Operations
-220.47
-1066.53%
-18.90
-853.29%
2.51
-60.02%
6.28
Depreciation Amortization Depletion
11.92
+21.61%
9.80
+126.10%
4.33
+58.58%
2.73
Depreciation
4.91
+94.38%
2.53
+12.57%
2.24
+84.39%
1.22
Amortization Cash Flow
7.01
-3.66%
7.27
+247.99%
2.09
+37.86%
1.52
Depreciation And Amortization
11.92
+21.61%
9.80
+126.10%
4.33
+58.58%
2.73
Amortization Of Intangibles
7.01
-3.66%
7.27
+247.99%
2.09
+37.86%
1.52
Other Non Cash Items
1.94
+105.39%
0.95
-54.84%
2.10
-14.70%
2.46
Stock Based Compensation
9.47
-23.79%
12.43
-11.45%
14.04
-13.75%
16.28
Deferred Tax
81.44
+1356.45%
-6.48
-404.04%
-1.29
-213.81%
1.13
Deferred Income Tax
81.44
+1356.45%
-6.48
-404.04%
-1.29
-213.81%
1.13
Operating Gains Losses
—
—
0.66
—
Gain Loss On Investment Securities
—
—
0.66
—
Change In Working Capital
8.31
+226.68%
-6.56
-777.91%
-0.75
-112.30%
6.07
Change In Receivables
-7.46
+42.65%
-13.01
-1740.45%
-0.71
+35.08%
-1.09
Changes In Account Receivables
-7.46
+42.65%
-13.01
-1740.45%
-0.71
+35.08%
-1.09
Change In Inventory
-3.47
-11851.72%
-0.03
+96.24%
-0.77
+82.79%
-4.48
Change In Prepaid Assets
-12.07
-77.04%
-6.82
-179.97%
8.52
+238.90%
-6.14
Change In Payables And Accrued Expense
15.82
+826.23%
1.71
+115.55%
-10.98
-193.14%
11.79
Change In Payable
15.82
+826.23%
1.71
+115.55%
-10.98
-193.14%
11.79
Change In Account Payable
15.82
+826.23%
1.71
+115.55%
-10.98
-193.14%
11.79
Change In Other Working Capital
15.48
+33.59%
11.59
+263.13%
3.19
-46.67%
5.99
Investing Cash Flow
94.86
+644.23%
-17.43
-44.58%
-12.06
-124.15%
49.92
Cash Flow From Continuing Investing Activities
94.86
+644.23%
-17.43
-44.58%
-12.06
-124.15%
49.92
Net PPE Purchase And Sale
-1.00
-103.67%
-0.49
-27.94%
-0.38
+43.59%
-0.68
Purchase Of PPE
-1.00
-103.67%
-0.49
-27.94%
-0.38
+43.59%
-0.68
Capital Expenditure
-1.00
-103.67%
-0.49
-27.94%
-0.38
+43.59%
-0.68
Net Investment Purchase And Sale
95.86
+854.13%
-12.71
-114.28%
88.99
+75.86%
50.60
Purchase Of Investment
-112.38
+69.19%
-364.77
+28.84%
-512.61
-46.77%
-349.26
Sale Of Investment
208.24
-40.85%
352.06
-41.48%
601.60
+50.45%
399.86
Net Business Purchase And Sale
—
—
-100.67
0.00
Purchase Of Business
—
—
-100.67
0.00
Net Other Investing Changes
—
-4.23
+95.80%
-100.67
—
Financing Cash Flow
-2.91
-1774.84%
-0.15
0.00
-100.00%
0.73
Cash Flow From Continuing Financing Activities
-2.91
-1774.84%
-0.15
0.00
-100.00%
0.73
Net Issuance Payments Of Debt
-1.99
-1184.52%
-0.15
0.00
0.00
Repayment Of Debt
-1.99
-1184.52%
-0.15
0.00
0.00
Long Term Debt Payments
-1.99
-1184.52%
-0.15
0.00
0.00
Net Long Term Debt Issuance
-1.99
-1184.52%
-0.15
0.00
0.00
Proceeds From Stock Option Exercised
—
0.00
0.00
-100.00%
0.73
Net Other Financing Charges
-0.92
—
—
—
Changes In Cash
-17.49
+47.55%
-33.34
-4575.44%
0.74
-99.10%
82.64
Effect Of Exchange Rate Changes
0.02
+114.11%
-0.16
-446.81%
0.05
-82.26%
0.27
Beginning Cash Position
102.78
-24.58%
136.29
+0.58%
135.50
+157.65%
52.59
End Cash Position
85.32
-16.99%
102.78
-24.58%
136.29
+0.58%
135.50
Free Cash Flow
-110.44
-579.76%
-16.25
-230.83%
12.42
-60.33%
31.30
Amortization Of Securities
-2.05
+70.65%
-6.99
+20.51%
-8.80
-196.96%
-2.96
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category